Professor Irv Weissman, M.D. - Founder & Board Member
Mark McCamish, M.D., Ph.D. - CEO & Board member
Ravindra Majeti, M.D., Ph.D. - founder & board member
Mark Chao, M.D., Ph.D. - Founder & SVP, Head of Clinical Development
Jens-Peter Volkmer, M.D. - Founder & VP of R&D
Founded
2015
Stage
Seed
Invested
2015
Status
IPO
Lightspeed Team
Christopher Schaepe - Partner
Jonathan MacQuitty - Partner
With a passion to help patients defeat their cancer, Forty Seven is committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
Company completed an IPO in 2018 and was acquired by Gilead Sciences, Inc. in 2020 for $4.9 billion.
Forty Seven
FractionFraction
Faction Ventures, LLC (“Faction”) and Lightspeed Management Company, L.L.C. (“Lightspeed”) are separate businesses that operate independently of each other. Faction is a registered investment adviser under the United States Investment Advisers Act of 1940, as amended. Faction advises its own fund(s) and does not advise any Lightspeed clients, and Lightspeed does not advise Faction or any of its clients. Lightspeed and Faction are parties to an agreement pursuant to which Lightspeed holds certain interests in Faction and the fund(s) Faction manages.
